Nicox S.A. (LON:0RCQ)

Market Cap	17.86M
Revenue (ttm)	6.20M
Net Income (ttm)	-18.12M
Shares Out	n/a
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	211
Average Volume	1,394
Open	0.306
Previous Close	0.307
Day's Range	0.306 - 0.313
52-Week Range	0.137 - 0.407
Beta	0.89
RSI	57.82
Earnings Date	Mar 19, 2025

About Nicox

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b ...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 28
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RCQ

Financial Performance

In 2023, Nicox's revenue was 7.14 million, an increase of 118.33% compared to the previous year's 3.27 million. Losses were -20.88 million, -24.78% less than in 2022.

Financial numbers in EUR